ArticleJournal of nanobiotechnology2025
Unveiling new therapeutic targets for esophageal cancer treatment through single-cell transcriptomics: pH-responsive nanobubbles enhance the efficacy of 125I radiotherapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates the mechanisms underlying the enhancement of radiosensitivity in esophageal carcinoma (ESCC) cells through the coupling of pH-responsive nanobubbles with Nivolumab, a CD8+ T cell activator.
methodsSingle-cell transcriptomics analysis was used to identify radiation-sensitive cancer cells in ESCC tissues. An in situ mouse model of ESCC was established to study the effects of radiation therapy on CD8+ T cells using high-throughput sequencing. Machine learning algorithms were employed to identify key genes associated with ESCC. CRISPR/Cas9 technology was used to knock out key genes, while lentivirus was used to overexpress them. In vitro assays were conducted to evaluate the impact of these key genes on CD8+ T cell activity, proliferation, migration, invasion, apoptosis, and sensitivity to radiation therapy. Nanobubbles conjugated with antibodies were prepared and their uptake by CD8+ T cells was observed. A humanized mouse model of ESCC was used to assess the effectiveness of the nanobubbles in enhancing CD8+ T cell activity and cytotoxicity.
resultsThe analysis revealed a close relationship between tumor cell radiosensitivity and CD8+ T cells. The key gene PD-1 was found to play a resistant role in the response to radiation therapy. PD-1 inhibited the activity and cytotoxicity of CD8+ T cells in ESCC tissues. The development of pH-responsive nanobubbles conjugated with Nivolumab (αPD1-O2-nivolumab (NB), enhanced CD8+ T cell cytotoxicity and increased the sensitivity of ESCC cells to radiation therapy. The release of oxygen by the nanobubbles further improved the efficacy of Nivolumab. In vivo experiments confirmed that αPD1-O2-NB increased CD8+ T cell activity and cytotoxicity, thereby improving the sensitivity of ESCC cells to radiation therapy.
conclusionPD-1 promotes resistance to radiation therapy in ESCC cells by suppressing the activity and cytotoxicity of CD8+ T cells. pH-responsive αPD1-O2-NB enhance CD8+ T cell activity and improve the sensitivity of ESCC cells to radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.